Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Oculis Holding AG OCS

Healthcare Biotechnology
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases in Switzerland, Iceland, and internationally. The company’s lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b... see more

Current News (NDAQ:OCS)

Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthalmology and Ophthalmology at the 2026 J.P. Morgan Healthcare Conference

GlobeNewswire 5 days ago

Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis

GlobeNewswire 7 days ago

Oculis Reports Q3 2025 Financial Results and Provides Company Update

GlobeNewswire November 10, 2025

Oculis to Participate in Upcoming November Investor Conferences

GlobeNewswire November 5, 2025

Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development

GlobeNewswire October 30, 2025

Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025

GlobeNewswire October 14, 2025

Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy

GlobeNewswire October 6, 2025

Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS

GlobeNewswire September 22, 2025

Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025

GlobeNewswire September 4, 2025
View More News ››

Opinion & Analysis (NDAQ:OCS)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:OCS)

Be the first to post on this bullboard.

NU E Power Corp

NU E Power Corp

NU E Power Corp. develops, owns, and operates renewable energy projects in Canada. It is involved in the development of solar ...
View More »

Podcasts